{"gene":"FGF23","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2006,"finding":"Klotho binds FGF23 and converts FGFR1(IIIc) into a specific high-affinity FGF23 receptor; forced expression of Klotho enabled high-affinity FGF23 binding to cell surfaces and restored FGF23 responsiveness in a renal cell line. Injection of an anti-Klotho monoclonal antibody in wild-type mice induced FGF23 incompetence, establishing Klotho as an obligate co-receptor for endogenous FGF23 function.","method":"Renal homogenate binding assay, cell-surface binding with forced Klotho expression, in vivo antibody neutralization, reconstitution of FGFR1(IIIc)/Klotho complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of receptor complex, in vitro binding assays, in vivo antibody neutralization, multiple orthogonal methods in a single rigorous study","pmids":["17086194"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of a 1:1:1 ternary complex of shed α-klotho ectodomain, FGFR1c ligand-binding domain, and FGF23 shows that α-klotho simultaneously tethers FGFR1c via its D3 domain and FGF23 via its C-terminal tail, conferring complex stability. Dimerization and receptor activation still require heparan sulfate. The α-klotho structure is incompatible with glycosidase activity, establishing it as a non-enzymatic scaffold protein.","method":"X-ray crystallography (atomic structure of ternary complex), structural functional validation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic resolution crystal structure with mechanistic interpretation, single rigorous study with direct structural evidence","pmids":["29342138"],"is_preprint":false},{"year":2011,"finding":"FGF23 causes pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway in a klotho-independent manner. Intramyocardial or intravenous FGF23 injection in wild-type mice produced LVH. Treatment with an FGF-receptor blocker attenuated LVH in a CKD model.","method":"Isolated rat cardiomyocyte hypertrophy assay, intramyocardial/intravenous FGF23 injection in mice, FGF-receptor blocker treatment in CKD animal model, klotho-deficient mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro cardiomyocyte assay with pathway identification, multiple in vivo mouse models, pharmacological blockade, replicated across several experimental systems in one study","pmids":["21985788"],"is_preprint":false},{"year":2017,"finding":"FGF23 induces cardiac hypertrophy and LVH specifically via FGFR4 (not other FGFRs); specific pharmacological blockade of FGFR4 attenuated established LVH in the 5/6 nephrectomy CKD rat model and protected aging mice from LVH. FGF23 also increases cardiac contractility via FGFR4.","method":"FGFR4-specific pharmacological blockade in CKD rat model (5/6 nephrectomy), FGFR4 knockout aging mice, in vitro cardiomyocyte assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and pharmacological blockade in multiple in vivo models with defined phenotypic readouts","pmids":["28512310"],"is_preprint":false},{"year":2014,"finding":"FGF23 directly regulates membrane abundance of the Na+:Cl- cotransporter NCC in distal renal tubules via a signaling cascade involving the FGF receptor/αKlotho complex → ERK1/2 → SGK1 → WNK4. Gain of FGF23 function increased distal tubular Na+ uptake and NCC membrane expression, causing volume expansion, hypertension, and cardiac hypertrophy in an αKlotho- and dietary Na+-dependent fashion. NCC inhibitor chlorothiazide abrogated these effects.","method":"Recombinant FGF23 injection in wild-type mice, Fgf23- and αKlotho-deficient mouse models, Hyp mice, pharmacological NCC inhibition, western blot for NCC membrane expression","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mouse models (loss- and gain-of-function), defined signaling cascade, pharmacological rescue, multiple orthogonal methods","pmids":["24797667"],"is_preprint":false},{"year":2016,"finding":"FGF23 inhibits neutrophil (PMN) recruitment by binding FGFR2 on PMNs, activating protein kinase A (PKA), and thereby inhibiting activation of the small GTPase Rap1, which counteracts selectin- and chemokine-triggered β2 integrin activation. FGF23 neutralization in CKD mice restored leukocyte recruitment; FGFR2 knockdown on PMNs rescued host defense.","method":"Intravital microscopy, in vitro PMN adhesion/arrest/migration assays, FGF23 neutralization in CKD mouse models, FGFR2 knockdown, PKA knockdown","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vitro and in vivo methods, defined signaling pathway (FGFR2→PKA→Rap1→β2 integrin), genetic knockdown validation","pmids":["26878171"],"is_preprint":false},{"year":2005,"finding":"FGF23-induced reductions in renal NaPi2a (sodium-phosphate cotransporter type IIa) expression and 1α-hydroxylase mRNA are independent of the 1,25(OH)2D/VDR signaling system, demonstrated by FGF23 administration to VDR-null mice. FGF23 production is regulated by VDR-independent pathways including calcium, whereas dietary phosphate-stimulated FGF23 production required VDR.","method":"Recombinant FGF23 administration to VDR knockout mice, measurement of NaPi2a protein abundance, 1α-hydroxylase and 24-hydroxylase mRNA, dietary manipulation","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout model with recombinant protein administration, multiple molecular endpoints, VDR-independent mechanism clearly established","pmids":["15998839"],"is_preprint":false},{"year":2020,"finding":"Kidney-derived glycerol-3-phosphate (G-3-P) stimulates bone and bone marrow FGF23 production through local GPAT-mediated lysophosphatidic acid (LPA) synthesis, which acts via LPA receptor 1 (LPAR1). Acute kidney injury rapidly increased circulating G-3-P, and the AKI-induced rise in FGF23 was abrogated by GPAT inhibition or Lpar1 deletion.","method":"Aptamer-based proteomics and LC-MS metabolomics of human renal venous plasma, exogenous G-3-P administration in mice, GPAT inhibition, Lpar1 genetic deletion, AKI mouse models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — human metabolomics identifying G-3-P, mechanistic validation in mice with genetic deletion and pharmacological inhibition across multiple orthogonal methods","pmids":["32065590"],"is_preprint":false},{"year":2023,"finding":"C-terminal FGF23 (Cter-FGF23) cleaved peptides, derived mainly from osteocytes via furin-dependent cleavage, bind BMP2 and BMP9 and prevent BMP-induced hepcidin production in the liver, thereby increasing iron availability during acute inflammation. Osteocyte-specific Fgf23 deletion and osteocyte-specific Furin deletion both reduced Cter-FGF23 and worsened iron deficiency during inflammation.","method":"Osteocyte-specific Fgf23 and Furin knockout mice, co-administration of Cter-FGF23 with BMP2/BMP9, genetic overexpression of Cter-Fgf23, measurement of hepcidin and serum iron","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mouse models (osteocyte-specific KO), BMP binding shown, mechanistic pathway established with multiple orthogonal approaches","pmids":["37053547"],"is_preprint":false},{"year":2021,"finding":"FGF23 undergoes FAM20C-mediated phosphorylation that targets it to proteolysis by the subtilisin-like proprotein convertase FURIN, resulting in secretion of FGF23 fragments. O-glycosylation of FGF23 by GALNT3 prevents this proteolysis, resulting in secretion of biologically active intact FGF23.","method":"Review synthesizing genetic/biochemical evidence from prior studies; described as established mechanisms from multiple prior works","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mechanistic details compiled from established literature but this paper is a review; individual supporting experiments are in primary sources not independently assessed here","pmids":["33338030"],"is_preprint":false},{"year":2014,"finding":"Pro-inflammatory cytokines TNF, IL-1β, TWEAK, and bacterial LPS up-regulate Fgf23 mRNA in osteocyte-like IDG-SW3 cells and human bone via NF-κB-dependent mechanisms. These stimuli also increased GALNT3 expression (which protects FGF23 from cleavage), and intact FGF23 protein increased in the presence of furin inhibitors, indicating that furin-mediated cleavage critically controls active FGF23 secretion.","method":"IDG-SW3 osteocyte cell line stimulation, human bone samples, qRT-PCR, ELISA, NF-κB inhibition, furin inhibition assays","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell culture and human tissue, NF-κB pathway validated pharmacologically, furin cleavage role shown with inhibitor, two orthogonal approaches in single lab","pmids":["25458698"],"is_preprint":false},{"year":2014,"finding":"Osteocyte-specific deletion of FGFR1 (Fgfr1Dmp1-cKO) reduced FGF23 expression in bone by 50% and serum FGF23 by 3-fold. FGF23 promoter activity in osteoblasts was stimulated by FGFR1 activation and inhibited by dominant-negative FGFR1(TK-), PLCγ, and MAPK inhibitors. FGF2 stimulated FGF23 translation via a FGFR1- and PI3K/Akt-dependent mechanism, establishing autocrine/paracrine FGFR1 signaling as a regulator of FGF23 production.","method":"Osteocyte-specific conditional Fgfr1 knockout (Dmp1-Cre), TOPflash luciferase reporter, FGF23 promoter-luciferase assay, dominant-negative FGFR1 overexpression, pharmacological pathway inhibitors","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockout in vivo combined with in vitro reporter assays and pharmacological pathway dissection, multiple orthogonal approaches","pmids":["25089825"],"is_preprint":false},{"year":2010,"finding":"FGF23 activates the Raf/MEK/ERK signaling pathway and induces EGR1 expression via FGFR1 in HEK293 cells, and also phosphorylates FRS2α. Extracellular phosphate activates the same cascade via PiT-1 (type III Na+/Pi cotransporter) converging on FGFR1, with FGFR1 knockdown abolishing Pi-induced ERK1/2 and FRS2α phosphorylation.","method":"HEK293 cell transfection with recombinant proteolysis-resistant FGF23[R179Q], ERK1/2 phosphorylation assays, FRS2α phosphorylation, FGFR1 knockdown, FGFR1 overexpression, PiT-1 knockdown, MEK inhibitor","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple knockdown and overexpression experiments in cell culture, defined signaling cascade, single lab","pmids":["20717920"],"is_preprint":false},{"year":2009,"finding":"FGF23 acts on the parathyroid gland via the Klotho-FGFR1c receptor complex to decrease PTH mRNA expression and PTH secretion through activation of the MAPK pathway. In CKD, parathyroid resistance to FGF23 is caused by down-regulation of the Klotho-FGFR1 complex in hyperplastic parathyroid glands.","method":"Parathyroid cell experiments, MAPK pathway activation assays, Klotho-FGFR1 expression analysis in CKD parathyroid tissue (human and animal)","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway identified (MAPK) in parathyroid cells, human and animal tissue analysis, but largely a review with primary experimental citations; single lab evidence for resistance mechanism","pmids":["20010546"],"is_preprint":false},{"year":2012,"finding":"FGF23 acts directly on the parathyroid gland via the Klotho-FGFR1 complex to decrease PTH synthesis and secretion through activation of the MAPK pathway. In advanced experimental uremia, parathyroids do not respond to administered FGF23 by MAPK activation or PTH inhibition, correlating with down-regulation of parathyroid Klotho-FGFR1. PTH directly increases FGF23 expression by osteoblast-like cells, and parathyroidectomy reduces FGF23 in CKD models.","method":"FGF23 administration to uremic rats, MAPK pathway activation assays in parathyroid tissue, parathyroidectomy experiments, osteoblast culture with PTH","journal":"Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro experiments with signaling pathway validation, but review chapter summarizing work from one group","pmids":["22396164"],"is_preprint":false},{"year":2015,"finding":"Phosphate directly enhances Fgf23 transcription in UMR-106 osteoblastic cells by stimulating NADPH oxidase-induced reactive oxygen species (ROS) production, which activates the MEK-ERK signaling pathway. Phosphonoformate (sodium-phosphate cotransporter inhibitor), NADPH oxidase inhibitor apocynin, and MEK inhibitor PD98059 all blocked phosphate-induced Fgf23 expression and promoter activity. Phosphate did not affect Fgf23 mRNA stability.","method":"UMR-106 cell culture, Fgf23 promoter-luciferase assay, ROS measurement (fluorescence), pharmacological inhibitors (apocynin, PD98059, phosphonoformate), mRNA stability assay","journal":"Journal of bone and mineral metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assay plus ROS measurement plus multiple pharmacological inhibitors, single lab, cell culture only","pmids":["25792238"],"is_preprint":false},{"year":2016,"finding":"Aldosterone up-regulates Fgf23 transcription and secretion via mineralocorticoid receptor activation, involving SGK1, NF-κB, and store-operated Ca2+ entry (SOCE). In osteoblastic UMR-106 cells, aldosterone enhanced SOCE and Fgf23 mRNA, effects reversed by mineralocorticoid receptor blockers (spironolactone, eplerenone), SGK1 inhibitor, NF-κB inhibitor, and Ca2+ channel blocker. In vivo, DOCA treatment and salt depletion elevated serum FGF23.","method":"UMR-106 cell culture, Fura-2 Ca2+ imaging, SOCE measurement, qRT-PCR, DOCA treatment and salt depletion in mice, serum FGF23 ELISA","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro pathway dissection with multiple pharmacological inhibitors, in vivo confirmation, single lab","pmids":["26773502"],"is_preprint":false},{"year":2019,"finding":"FGF23 promotes cardiac hypertrophy via FGF receptor 4-dependent activation of phospholipase Cγ/calcineurin/NFAT signaling, independent of klotho. FGF23 expressed in cardiac myocytes also stimulates pro-fibrotic factors in myocytes to induce fibrosis-related pathways in fibroblasts in a paracrine manner.","method":"In vitro neonatal rat ventricular myocyte (NRVM) hypertrophy assays, FGFR4 blockade, PLCγ/calcineurin/NFAT pathway analysis, co-culture experiments","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling pathway, in vitro assays, pharmacological blockade, but review paper synthesizing findings; primary experiments from multiple labs","pmids":["29892269"],"is_preprint":false},{"year":2019,"finding":"FGF23-mediated activation of local renin-angiotensin-aldosterone system (RAAS) in the heart promotes cardiac hypertrophy and fibrosis. In neonatal rat ventricular myocytes and fibroblasts, FGF23 stimulated RAAS gene expression; FGF23-mediated hypertrophy and NFAT target gene induction were attenuated by cyclosporine A, losartan, and spironolactone. FGF23 also induced TGF-β and CTGF in cardiac fibroblasts, suppressed by losartan and spironolactone.","method":"5/6 nephrectomy rat model, neonatal rat ventricular myocytes and cardiac fibroblasts (NRVM, NRCF), qPCR, western blot, pharmacological inhibition (losartan, spironolactone, cyclosporine A)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo CKD model and in vitro cell assays, pharmacological rescue, single lab","pmids":["31540546"],"is_preprint":false},{"year":2018,"finding":"FGF23 activates nuclear Ca2+-regulated CaMKII-HDAC4 pathway and induces IP3-mediated Ca2+ release from nucleoplasmic Ca2+ stores in neonatal rat ventricular myocytes (NRVMs), similar to angiotensin II. FGF23-induced hypertrophy was attenuated by losartan (ATII receptor antagonist), and FGF23 increased intracellular ATII peptide expression and secretion in NRVMs, suggesting FGF23-mediated hypertrophy involves local angiotensin II production.","method":"NRVM Ca2+ imaging, cell area measurement, hypertrophic gene expression, losartan treatment, ATII peptide measurement","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined Ca2+ signaling pathway, pharmacological rescue with ATII receptor blocker, single lab, in vitro only","pmids":["30062428"],"is_preprint":false},{"year":2021,"finding":"During acute kidney injury, hepatic FGF23 production is driven by the orphan nuclear receptor ERR-γ, which is induced by circulating IL-6. Ectopic ERR-γ overexpression was sufficient to induce hepatic FGF23. Liver-specific ERRγ knockout or ERRγ inverse agonist treatment decreased hepatic FGF23 mRNA and plasma FGF23 levels in AKI mice.","method":"Folic acid-induced AKI mouse model, liver-specific ERRγ knockout, ERRγ overexpression, IL-6 neutralizing antibody and recombinant IL-6 administration, ERRγ inverse agonist","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout, ectopic overexpression, cytokine neutralization, pharmacological inhibition, and human patient correlation, multiple orthogonal methods","pmids":["33853949"],"is_preprint":false},{"year":2024,"finding":"Hepatic FGF23 is transcriptionally regulated by ERR-γ in response to alcohol-mediated activation of cannabinoid receptor type 1 (CB1R). FGF23-LKO mice showed decreased hepatic CYP2E1 expression, reduced oxidative stress, and improved alcoholic liver disease, establishing a CB1R-ERRγ-FGF23-CYP2E1 axis in alcoholic liver injury.","method":"Hepatocyte-specific knockouts (CB1R-LKO, ERRγ-LKO, FGF23-LKO), chronic alcohol feeding, ERRγ inverse agonist treatment, CYP2E1 expression analysis, liver injury assessment","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple tissue-specific genetic knockouts, pharmacological inhibition, defined CB1R→ERRγ→FGF23→CYP2E1 pathway with mechanistic validation","pmids":["38479224"],"is_preprint":false},{"year":2015,"finding":"FGF23 signals through a klotho/FGFR complex in multiple myeloma cells (expressing both klotho and FGFR), increasing EGR1 and its target heparanase mRNA. FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23 and suppressed myeloma growth in bone.","method":"MM cell line stimulation with FGF23, mRNA expression (EGR1, heparanase), FGFR inhibitor NVP-BGJ398, in vivo bone growth model, klotho/FGFR expression analysis by IHC and western blot","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro signaling assays, pharmacological FGFR blockade in vitro and in vivo, single lab","pmids":["25944690"],"is_preprint":false},{"year":2020,"finding":"High extracellular phosphate directly activates FGFR1 in osteocytes/osteoblasts, and downstream intracellular signaling regulates GALNT3 expression, which in turn controls O-glycosylation and the ratio of intact to cleaved FGF23. FGFR1 thus functions as a phosphate-sensing receptor in the regulation of FGF23 production.","method":"Cell culture experiments with phosphate stimulation, FGFR1 activation assays, GALNT3 expression analysis, FGF23 protein cleavage measurements","journal":"Journal of endocrinological investigation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — described in a review/perspective with reference to authors' own prior findings; limited methodological detail in this abstract, single lab","pmids":["32140858"],"is_preprint":false},{"year":2019,"finding":"FGF23 deficiency in mice leads to hippocampal-dependent cognitive impairment (dose-dependent, established by behavioral testing) without gross structural or developmental brain defects, without change in hippocampal synaptic plasticity, and with only minor impairment to postnatal hippocampal neurogenesis, indicating a distinct brain phenotype from Klotho-deficient mice.","method":"Fgf23-deficient mouse model, hippocampal-dependent behavioral tests (cognitive), hippocampal neurogenesis assay, synaptic plasticity measurements","journal":"eNeuro","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cognitive phenotype in genetic knockout with multiple behavioral and cellular readouts, single lab","pmids":["30911673"],"is_preprint":false},{"year":2021,"finding":"C-terminal FGF23 (Cter-FGF23) peptide alleviates LPS-induced acute hypoferremia by reducing hepatic and circulating hepcidin. FGF23 is induced as early as pro-inflammatory cytokines by LPS (TLR4 activation), and inhibition of FGF23 signaling with C-terminal FGF23 tail abrogated iron sequestration in liver and spleen.","method":"Wild-type mouse LPS model, C-terminal FGF23 peptide administration, hepcidin mRNA and protein measurement, serum iron and transferrin saturation, tissue iron quantification","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological intervention with FGF23 C-tail, multiple iron metabolism endpoints, single lab","pmids":["32193252"],"is_preprint":false},{"year":2015,"finding":"FGF23 up-regulates AHSG (Fetuin-A) mRNA and protein production in osteocytes via FGF receptor-dependent mechanisms; FGF23 silencing had the opposite effect. FGF23 and AHSG proteins co-localize in both cytoplasm and nucleus of osteocytes, suggesting possible direct interaction.","method":"Osteocyte cell culture, FGF23 addition/overexpression/silencing, qRT-PCR, western blot, FGF23 receptor blockade, co-localization by immunofluorescence","journal":"Bone","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell culture only, single lab, co-localization without formal co-IP or pulldown for interaction","pmids":["26476373"],"is_preprint":false}],"current_model":"FGF23 is a bone-derived (primarily osteocyte-secreted) endocrine hormone that binds a ternary receptor complex of FGFR1c and the non-enzymatic scaffold co-receptor α-Klotho (structure resolved by X-ray crystallography), activating FRS2/RAS/RAF/MEK/ERK1/2 signaling to suppress renal NaPi-IIa/IIc-mediated phosphate reabsorption, inhibit 1α-hydroxylase (reducing 1,25(OH)2D synthesis), and augment distal tubular NCC/TRPV5 expression via ERK1/2→SGK1→WNK4 signaling; FGF23 also acts on the parathyroid via Klotho-FGFR1c to suppress PTH through MAPK activation, while at high concentrations (as in CKD) it acts on klotho-deficient tissues—most importantly the heart via FGFR4—activating calcineurin/NFAT and PLCγ pathways to cause left ventricular hypertrophy, and on neutrophils via FGFR2/PKA/Rap1 to suppress β2 integrin activation and impair innate immunity; FGF23 undergoes post-translational regulation by GALNT3-mediated O-glycosylation (promoting secretion of intact, active hormone) and FAM20C phosphorylation/furin cleavage (producing inactive C-terminal fragments), with the C-terminal fragments having their own biological activity by binding BMP2/BMP9 to suppress hepcidin and increase iron availability during inflammation."},"narrative":{"mechanistic_narrative":"FGF23 is a bone-derived endocrine hormone that controls systemic phosphate and vitamin D homeostasis and, at pathological concentrations, drives organ injury in chronic kidney disease [PMID:17086194, PMID:15998839]. Canonical FGF23 signaling requires the co-receptor α-Klotho, which converts FGFR1c into a high-affinity FGF23 receptor; structurally, α-Klotho is a non-enzymatic scaffold that simultaneously tethers FGFR1c and the FGF23 C-terminal tail, with heparan sulfate required for receptor dimerization and activation [PMID:17086194, PMID:29342138]. Through this Klotho-FGFR1c complex FGF23 activates RAS/RAF/MEK/ERK signaling to suppress renal NaPi-IIa and 1α-hydroxylase—independently of vitamin D/VDR signaling [PMID:15998839, PMID:20717920]—and acts on distal tubule to raise NCC membrane abundance via ERK1/2→SGK1→WNK4, causing Na+ retention, hypertension, and cardiac hypertrophy [PMID:24797667]; it also acts directly on the parathyroid gland via Klotho-FGFR1 to suppress PTH through MAPK activation [PMID:20010546]. In Klotho-independent settings, high FGF23 drives left ventricular hypertrophy by signaling through cardiac FGFR4 to activate PLCγ/calcineurin/NFAT, with FGFR4 blockade attenuating established LVH [PMID:21985788, PMID:28512310], and suppresses neutrophil recruitment by binding FGFR2 and activating PKA to inhibit Rap1-dependent β2 integrin activation, impairing innate immunity [PMID:26878171]. FGF23 production by osteocytes is regulated by autocrine/paracrine FGFR1 signaling and by phosphate, PTH, aldosterone, and pro-inflammatory cytokines acting through NF-κB, ROS/MEK-ERK, and SGK1 pathways [PMID:25089825, PMID:25792238, PMID:26773502, PMID:25458698], while post-translational processing—FAM20C phosphorylation and furin cleavage versus GALNT3 O-glycosylation—determines the ratio of inactive fragments to secreted intact hormone [PMID:33338030]. The furin-generated C-terminal fragment is itself bioactive, binding BMP2/BMP9 to block hepcidin induction and preserve iron availability during inflammation [PMID:37053547, PMID:32193252].","teleology":[{"year":2006,"claim":"Established why FGF23 is tissue-selective despite ubiquitous FGFRs: α-Klotho is an obligate co-receptor that converts FGFR1c into a high-affinity FGF23 receptor.","evidence":"Renal binding assays, forced Klotho expression, and in vivo anti-Klotho antibody neutralization in mice","pmids":["17086194"],"confidence":"High","gaps":["Did not resolve the atomic architecture of the ternary complex","Did not address Klotho-independent FGF23 actions"]},{"year":2018,"claim":"Resolved the structural basis of receptor assembly, showing α-Klotho is a non-enzymatic scaffold tethering both FGFR1c and the FGF23 C-terminal tail.","evidence":"X-ray crystallography of the 1:1:1 shed α-Klotho/FGFR1c/FGF23 ternary complex with functional validation","pmids":["29342138"],"confidence":"High","gaps":["Heparan sulfate-bound dimeric activated state not crystallized","Structures of FGFR4 and FGFR2 complexes not defined"]},{"year":2005,"claim":"Showed FGF23 suppresses renal phosphate transport and 1α-hydroxylase through a VDR-independent mechanism, separating its effector actions from vitamin D signaling.","evidence":"Recombinant FGF23 administration to VDR-null mice with measurement of NaPi2a, 1α- and 24-hydroxylase mRNA","pmids":["15998839"],"confidence":"High","gaps":["Did not define the renal intracellular signaling cascade","Dietary phosphate-stimulated FGF23 production was VDR-dependent, mechanism unresolved"]},{"year":2010,"claim":"Defined the canonical FGF23 intracellular cascade and linked it to phosphate sensing through a converging FGFR1 node.","evidence":"HEK293 transfection with proteolysis-resistant FGF23[R179Q], ERK1/2 and FRS2α phosphorylation, FGFR1 and PiT-1 knockdown","pmids":["20717920"],"confidence":"Medium","gaps":["Cell line overexpression, not physiological target tissue","Did not require Klotho in this system"]},{"year":2011,"claim":"Identified a Klotho-independent pathological action of FGF23, demonstrating it directly causes cardiomyocyte hypertrophy via FGFR-dependent calcineurin-NFAT signaling.","evidence":"Isolated rat cardiomyocyte assays, intramyocardial/IV FGF23 injection, FGF-receptor blockade in a CKD model","pmids":["21985788"],"confidence":"High","gaps":["Did not pinpoint which FGFR mediates the cardiac effect","Did not establish PLCγ upstream of calcineurin"]},{"year":2014,"claim":"Mapped the receptor and signaling specificity of FGF23-induced renal Na+ handling, connecting FGF23 to hypertension and volume expansion.","evidence":"Gain- and loss-of-function mouse models, NCC membrane western blots, chlorothiazide rescue","pmids":["24797667"],"confidence":"High","gaps":["Did not reconcile the αKlotho-dependent renal effect with Klotho-independent cardiac effects","Long-term cardiovascular consequences not fully traced"]},{"year":2014,"claim":"Established autocrine/paracrine FGFR1 signaling within bone as a positive regulator of FGF23 production, identifying a feed-forward loop.","evidence":"Osteocyte-specific Fgfr1 conditional knockout, FGF23 promoter-luciferase assays, dominant-negative FGFR1 and pathway inhibitors","pmids":["25089825"],"confidence":"High","gaps":["Upstream physiological ligand activating osteocyte FGFR1 not defined","Quantitative contribution relative to systemic regulators unclear"]},{"year":2014,"claim":"Linked inflammation to FGF23 production, showing cytokines and LPS induce Fgf23 via NF-κB while furin cleavage gates active hormone output.","evidence":"IDG-SW3 osteocyte stimulation and human bone, qRT-PCR/ELISA, NF-κB and furin inhibitors","pmids":["25458698"],"confidence":"Medium","gaps":["Single-lab cell and tissue model","In vivo causal contribution of NF-κB not tested by genetic deletion"]},{"year":2015,"claim":"Refined how phosphate transcriptionally induces FGF23, implicating NADPH oxidase-derived ROS upstream of MEK-ERK.","evidence":"UMR-106 promoter-luciferase, ROS imaging, apocynin/PD98059/phosphonoformate inhibitors, mRNA stability assay","pmids":["25792238"],"confidence":"Medium","gaps":["Cell culture only","Did not connect ROS pathway to FGFR1-mediated phosphate sensing"]},{"year":2016,"claim":"Identified aldosterone/mineralocorticoid receptor as a hormonal driver of FGF23, involving SGK1, NF-κB, and store-operated Ca2+ entry.","evidence":"UMR-106 culture, Fura-2 Ca2+ imaging, MR/SGK1/NF-κB/Ca2+-channel inhibitors, DOCA and salt depletion in mice","pmids":["26773502"],"confidence":"Medium","gaps":["Single-lab mechanism","Tissue-specific genetic confirmation of MR-FGF23 axis lacking"]},{"year":2016,"claim":"Defined a Klotho-independent immunosuppressive action of FGF23, showing it impairs neutrophil recruitment through FGFR2/PKA/Rap1.","evidence":"Intravital microscopy, PMN adhesion assays, FGF23 neutralization in CKD mice, FGFR2 and PKA knockdown","pmids":["26878171"],"confidence":"High","gaps":["Structural basis of FGF23-FGFR2 engagement not resolved","Relative clinical contribution to CKD infection risk not quantified"]},{"year":2017,"claim":"Identified FGFR4 as the specific cardiac receptor for FGF23-induced hypertrophy, providing a therapeutic target.","evidence":"FGFR4-specific blockade in 5/6 nephrectomy rats, FGFR4 knockout aging mice, in vitro cardiomyocyte assays","pmids":["28512310"],"confidence":"High","gaps":["Did not fully delineate downstream effectors in this study","Whether contractility and hypertrophy share one pathway unresolved"]},{"year":2018,"claim":"Connected FGF23 cardiac signaling to nuclear Ca2+/CaMKII-HDAC4 and local angiotensin II, linking it to a hypertrophic gene program.","evidence":"NRVM Ca2+ imaging, cell area and hypertrophic gene readouts, losartan treatment, ATII peptide measurement","pmids":["30062428"],"confidence":"Medium","gaps":["In vitro only","Causal role of local ATII in vivo not established"]},{"year":2019,"claim":"Extended the cardiac mechanism, implicating FGFR4-PLCγ/calcineurin/NFAT and local RAAS activation in hypertrophy and fibrosis.","evidence":"5/6 nephrectomy rats and NRVM/NRCF cultures, losartan/spironolactone/cyclosporine A inhibition (and review synthesis)","pmids":["29892269","31540546"],"confidence":"Medium","gaps":["Single-lab in vitro emphasis","Integration of RAAS, Ca2+, and NFAT into one circuit not fully resolved"]},{"year":2019,"claim":"Revealed a non-mineral CNS phenotype, showing FGF23 deficiency causes hippocampal-dependent cognitive impairment distinct from Klotho loss.","evidence":"Fgf23-deficient mice, hippocampal behavioral testing, neurogenesis and synaptic plasticity assays","pmids":["30911673"],"confidence":"Medium","gaps":["Receptor and signaling pathway in brain unidentified","Cell-autonomous vs systemic mechanism unresolved"]},{"year":2020,"claim":"Identified a kidney-to-bone metabolite signal, glycerol-3-phosphate acting via LPA/LPAR1, that drives FGF23 production, especially in acute kidney injury.","evidence":"Human renal venous metabolomics, exogenous G-3-P in mice, GPAT inhibition, Lpar1 deletion, AKI models","pmids":["32065590"],"confidence":"High","gaps":["Intracellular LPAR1-to-FGF23 transcription link not detailed","Relative importance versus phosphate/PTH regulation unclear"]},{"year":2021,"claim":"Defined a hepatic source of FGF23 in injury, showing IL-6-induced ERR-γ transcriptionally drives liver FGF23 during AKI.","evidence":"Folic acid AKI model, liver-specific ERRγ knockout, ERRγ overexpression, IL-6 neutralization, ERRγ inverse agonist","pmids":["33853949"],"confidence":"High","gaps":["Functional consequence of hepatic vs bone FGF23 not separated","Whether hepatic FGF23 is intact or cleaved not defined here"]},{"year":2021,"claim":"Established a distinct bioactivity for the C-terminal FGF23 fragment in iron metabolism, alleviating inflammatory hypoferremia by lowering hepcidin.","evidence":"WT mouse LPS model, C-terminal FGF23 peptide administration, hepcidin and tissue/serum iron measurements","pmids":["32193252"],"confidence":"Medium","gaps":["Molecular receptor/binding partner of the fragment not identified in this study","Single-lab pharmacological intervention"]},{"year":2021,"claim":"Consolidated the post-translational control of FGF23 output via FAM20C phosphorylation/furin cleavage versus GALNT3 O-glycosylation.","evidence":"Review synthesizing prior genetic and biochemical evidence","pmids":["33338030"],"confidence":"Medium","gaps":["Review, not primary data","Relative in vivo flux through each branch not quantified"]},{"year":2023,"claim":"Provided direct molecular mechanism for C-terminal FGF23 bioactivity, showing it binds BMP2/BMP9 to block BMP-induced hepcidin and preserve iron during inflammation.","evidence":"Osteocyte-specific Fgf23 and Furin knockouts, Cter-FGF23 plus BMP2/BMP9 co-administration, Cter-Fgf23 overexpression, hepcidin/iron measurement","pmids":["37053547"],"confidence":"High","gaps":["Structural basis of Cter-FGF23/BMP binding not resolved","Contribution in chronic vs acute inflammation not delineated"]},{"year":2024,"claim":"Extended hepatic FGF23 regulation to alcoholic liver disease through a CB1R-ERRγ-FGF23-CYP2E1 oxidative-stress axis.","evidence":"Hepatocyte-specific CB1R/ERRγ/FGF23 knockouts, chronic alcohol feeding, ERRγ inverse agonist, CYP2E1 and injury readouts","pmids":["38479224"],"confidence":"High","gaps":["Receptor mediating FGF23-to-CYP2E1 effect not defined","Whether circulating vs autocrine hepatic FGF23 is responsible unclear"]},{"year":null,"claim":"How the distinct receptor usage (FGFR1c/Klotho, FGFR4, FGFR2) and the intact-versus-C-terminal forms are integrated to produce tissue-specific physiological versus pathological outcomes remains unresolved.","evidence":"No single study reconciles receptor selectivity, fragment bioactivity, and tissue context","pmids":[],"confidence":"Low","gaps":["No unified model of receptor/cofactor selection across tissues","Endogenous receptor for the C-terminal fragment's hepcidin effect not molecularly defined","Brain FGF23 signaling pathway unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,5]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,4,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,25]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,4,5,12]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[4,6]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,8,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,20,21]}],"complexes":["FGF23–FGFR1c–α-Klotho ternary receptor complex"],"partners":["KL","FGFR1","FGFR4","FGFR2","BMP2","BMP9","GALNT3","FURIN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9GZV9","full_name":"Fibroblast growth factor 23","aliases":["Phosphatonin","Tumor-derived hypophosphatemia-inducing factor"],"length_aa":251,"mass_kda":28.0,"function":"Regulator of phosphate homeostasis (PubMed:11062477). Inhibits renal tubular phosphate transport by reducing SLC34A1 levels (PubMed:11409890). Up-regulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism (PubMed:15040831). Negatively regulates osteoblast differentiation and matrix mineralization (PubMed:18282132)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9GZV9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF23","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF23","total_profiled":1310},"omim":[{"mim_id":"621127","title":"BBX HIGH MOBILITY GROUP BOX DOMAIN-CONTAINING PROTEIN; BBX","url":"https://www.omim.org/entry/621127"},{"mim_id":"617994","title":"TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 3; HFTC3","url":"https://www.omim.org/entry/617994"},{"mim_id":"617993","title":"TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2","url":"https://www.omim.org/entry/617993"},{"mim_id":"616963","title":"HYPERCALCEMIA, INFANTILE, 2; HCINF2","url":"https://www.omim.org/entry/616963"},{"mim_id":"613312","title":"HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 2; ARHR2","url":"https://www.omim.org/entry/613312"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Centrosome","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"heart muscle","ntpm":5.4},{"tissue":"liver","ntpm":4.7}],"url":"https://www.proteinatlas.org/search/FGF23"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9GZV9","domains":[{"cath_id":"2.80.10.50","chopping":"40-170","consensus_level":"high","plddt":93.7266,"start":40,"end":170}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZV9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZV9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZV9-F1-predicted_aligned_error_v6.png","plddt_mean":76.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF23","jax_strain_url":"https://www.jax.org/strain/search?query=FGF23"},"sequence":{"accession":"Q9GZV9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9GZV9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9GZV9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZV9"}},"corpus_meta":[{"pmid":"21985788","id":"PMC_21985788","title":"FGF23 induces left ventricular hypertrophy.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21985788","citation_count":1610,"is_preprint":false},{"pmid":"17086194","id":"PMC_17086194","title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17086194","citation_count":1454,"is_preprint":false},{"pmid":"20059333","id":"PMC_20059333","title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.","date":"2010","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20059333","citation_count":504,"is_preprint":false},{"pmid":"29342138","id":"PMC_29342138","title":"α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29342138","citation_count":390,"is_preprint":false},{"pmid":"19844248","id":"PMC_19844248","title":"The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.","date":"2009","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19844248","citation_count":341,"is_preprint":false},{"pmid":"15998839","id":"PMC_15998839","title":"Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.","date":"2005","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15998839","citation_count":279,"is_preprint":false},{"pmid":"24797667","id":"PMC_24797667","title":"FGF23 regulates renal sodium handling and blood pressure.","date":"2014","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24797667","citation_count":256,"is_preprint":false},{"pmid":"12791601","id":"PMC_12791601","title":"FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.","date":"2003","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12791601","citation_count":251,"is_preprint":false},{"pmid":"26878171","id":"PMC_26878171","title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26878171","citation_count":230,"is_preprint":false},{"pmid":"30808384","id":"PMC_30808384","title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity.","date":"2019","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30808384","citation_count":222,"is_preprint":false},{"pmid":"22421513","id":"PMC_22421513","title":"Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.","date":"2012","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22421513","citation_count":210,"is_preprint":false},{"pmid":"23774819","id":"PMC_23774819","title":"Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.","date":"2013","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/23774819","citation_count":209,"is_preprint":false},{"pmid":"29770125","id":"PMC_29770125","title":"FGF23 Actions on Target Tissues-With and Without Klotho.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29770125","citation_count":157,"is_preprint":false},{"pmid":"28785560","id":"PMC_28785560","title":"Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.","date":"2016","source":"Kidney diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28785560","citation_count":153,"is_preprint":false},{"pmid":"25458698","id":"PMC_25458698","title":"Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli.","date":"2014","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25458698","citation_count":147,"is_preprint":false},{"pmid":"33338030","id":"PMC_33338030","title":"FGF23 signalling and physiology.","date":"2021","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33338030","citation_count":137,"is_preprint":false},{"pmid":"27622885","id":"PMC_27622885","title":"FGF23-Klotho signaling axis in the kidney.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27622885","citation_count":131,"is_preprint":false},{"pmid":"21346724","id":"PMC_21346724","title":"Phosphate and FGF-23.","date":"2011","source":"Kidney international. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/21346724","citation_count":124,"is_preprint":false},{"pmid":"19626341","id":"PMC_19626341","title":"Overview of the FGF23-Klotho axis.","date":"2009","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19626341","citation_count":124,"is_preprint":false},{"pmid":"20010546","id":"PMC_20010546","title":"FGF23-parathyroid interaction: implications in chronic kidney disease.","date":"2009","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/20010546","citation_count":123,"is_preprint":false},{"pmid":"22339660","id":"PMC_22339660","title":"Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.","date":"2012","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/22339660","citation_count":114,"is_preprint":false},{"pmid":"23577141","id":"PMC_23577141","title":"Arterial klotho expression and FGF23 effects on vascular calcification and function.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23577141","citation_count":114,"is_preprint":false},{"pmid":"32065590","id":"PMC_32065590","title":"Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32065590","citation_count":112,"is_preprint":false},{"pmid":"28512310","id":"PMC_28512310","title":"FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28512310","citation_count":103,"is_preprint":false},{"pmid":"15470265","id":"PMC_15470265","title":"The wrickkened pathways of FGF23, MEPE and PHEX.","date":"2004","source":"Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists","url":"https://pubmed.ncbi.nlm.nih.gov/15470265","citation_count":102,"is_preprint":false},{"pmid":"29381780","id":"PMC_29381780","title":"X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.","date":"2018","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29381780","citation_count":99,"is_preprint":false},{"pmid":"37443358","id":"PMC_37443358","title":"FGF23 and klotho at the intersection of kidney and cardiovascular disease.","date":"2023","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37443358","citation_count":98,"is_preprint":false},{"pmid":"20798257","id":"PMC_20798257","title":"Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.","date":"2010","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/20798257","citation_count":98,"is_preprint":false},{"pmid":"19556340","id":"PMC_19556340","title":"Novel regulators of Fgf23 expression and mineralization in Hyp bone.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19556340","citation_count":98,"is_preprint":false},{"pmid":"25089825","id":"PMC_25089825","title":"Osteocyte-specific deletion of Fgfr1 suppresses FGF23.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25089825","citation_count":95,"is_preprint":false},{"pmid":"22983423","id":"PMC_22983423","title":"FGF23 production by osteocytes.","date":"2012","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22983423","citation_count":92,"is_preprint":false},{"pmid":"15863037","id":"PMC_15863037","title":"FGF23 and disorders of phosphate homeostasis.","date":"2005","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15863037","citation_count":92,"is_preprint":false},{"pmid":"29892269","id":"PMC_29892269","title":"Paracrine Effects of FGF23 on the Heart.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29892269","citation_count":87,"is_preprint":false},{"pmid":"26019137","id":"PMC_26019137","title":"FGF23 promotes prostate cancer progression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26019137","citation_count":83,"is_preprint":false},{"pmid":"27582104","id":"PMC_27582104","title":"Ironing out the cross talk between FGF23 and inflammation.","date":"2016","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27582104","citation_count":82,"is_preprint":false},{"pmid":"27178987","id":"PMC_27178987","title":"Update on FGF23 and Klotho signaling.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27178987","citation_count":81,"is_preprint":false},{"pmid":"31540546","id":"PMC_31540546","title":"FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31540546","citation_count":81,"is_preprint":false},{"pmid":"36624273","id":"PMC_36624273","title":"Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions.","date":"2023","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/36624273","citation_count":80,"is_preprint":false},{"pmid":"29025789","id":"PMC_29025789","title":"FGF23 and Left Ventricular Hypertrophy in Children with CKD.","date":"2017","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/29025789","citation_count":78,"is_preprint":false},{"pmid":"32188018","id":"PMC_32188018","title":"Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease.","date":"2020","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/32188018","citation_count":76,"is_preprint":false},{"pmid":"22714041","id":"PMC_22714041","title":"The role of FGF23 in CKD--with or without Klotho.","date":"2012","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/22714041","citation_count":75,"is_preprint":false},{"pmid":"26773502","id":"PMC_26773502","title":"Up-regulation of FGF23 release by aldosterone.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26773502","citation_count":74,"is_preprint":false},{"pmid":"27847255","id":"PMC_27847255","title":"FGF23-αKlotho as a paradigm for a kidney-bone network.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27847255","citation_count":72,"is_preprint":false},{"pmid":"20717920","id":"PMC_20717920","title":"Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20717920","citation_count":72,"is_preprint":false},{"pmid":"25498378","id":"PMC_25498378","title":"New insights into the FGF23-Klotho axis.","date":"2014","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/25498378","citation_count":68,"is_preprint":false},{"pmid":"33295878","id":"PMC_33295878","title":"FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.","date":"2021","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33295878","citation_count":64,"is_preprint":false},{"pmid":"27838783","id":"PMC_27838783","title":"The FGF23 and Klotho system beyond mineral metabolism.","date":"2016","source":"Clinical and experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27838783","citation_count":64,"is_preprint":false},{"pmid":"18660670","id":"PMC_18660670","title":"PHEX, FGF23, DMP1 and beyond.","date":"2008","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/18660670","citation_count":64,"is_preprint":false},{"pmid":"30664852","id":"PMC_30664852","title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting.","date":"2019","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/30664852","citation_count":61,"is_preprint":false},{"pmid":"30013515","id":"PMC_30013515","title":"FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30013515","citation_count":60,"is_preprint":false},{"pmid":"31199502","id":"PMC_31199502","title":"Regulation of fibroblast growth factor 23 (FGF23) in health and disease.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31199502","citation_count":59,"is_preprint":false},{"pmid":"20526631","id":"PMC_20526631","title":"FGF23 and the parathyroid glands.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20526631","citation_count":58,"is_preprint":false},{"pmid":"22396161","id":"PMC_22396161","title":"FGF23 and syndromes of abnormal renal phosphate handling.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22396161","citation_count":53,"is_preprint":false},{"pmid":"22573484","id":"PMC_22573484","title":"The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.","date":"2012","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/22573484","citation_count":52,"is_preprint":false},{"pmid":"36246903","id":"PMC_36246903","title":"PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: Genetics, epigenetics and beyond.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36246903","citation_count":52,"is_preprint":false},{"pmid":"28294047","id":"PMC_28294047","title":"Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White?","date":"2018","source":"Current vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28294047","citation_count":51,"is_preprint":false},{"pmid":"26864938","id":"PMC_26864938","title":"FGF23 from bench to bedside.","date":"2016","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26864938","citation_count":51,"is_preprint":false},{"pmid":"30504710","id":"PMC_30504710","title":"Phosphate Homeostasis, Inflammation and the Regulation of FGF-23.","date":"2018","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/30504710","citation_count":50,"is_preprint":false},{"pmid":"30909513","id":"PMC_30909513","title":"FGF23, Biomarker or Target?","date":"2019","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/30909513","citation_count":48,"is_preprint":false},{"pmid":"25792238","id":"PMC_25792238","title":"Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells.","date":"2015","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25792238","citation_count":48,"is_preprint":false},{"pmid":"34950827","id":"PMC_34950827","title":"FGF23 and Vitamin D Metabolism.","date":"2021","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/34950827","citation_count":47,"is_preprint":false},{"pmid":"31599133","id":"PMC_31599133","title":"FGF23 and Associated Disorders of Phosphate Wasting.","date":"2019","source":"Pediatric endocrinology reviews : PER","url":"https://pubmed.ncbi.nlm.nih.gov/31599133","citation_count":47,"is_preprint":false},{"pmid":"32982979","id":"PMC_32982979","title":"Osteocytic FGF23 and Its Kidney Function.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32982979","citation_count":45,"is_preprint":false},{"pmid":"31485552","id":"PMC_31485552","title":"FGF23, Hypophosphatemia, and Emerging Treatments.","date":"2019","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/31485552","citation_count":44,"is_preprint":false},{"pmid":"35084563","id":"PMC_35084563","title":"The regulation of FGF23 under physiological and pathophysiological conditions.","date":"2022","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35084563","citation_count":44,"is_preprint":false},{"pmid":"26746858","id":"PMC_26746858","title":"Phosphate and FGF-23.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/26746858","citation_count":42,"is_preprint":false},{"pmid":"30217676","id":"PMC_30217676","title":"FGF23 beyond Phosphotropic Hormone.","date":"2018","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/30217676","citation_count":40,"is_preprint":false},{"pmid":"30911673","id":"PMC_30911673","title":"FGF-23 Deficiency Impairs Hippocampal-Dependent Cognitive Function.","date":"2019","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/30911673","citation_count":40,"is_preprint":false},{"pmid":"26148725","id":"PMC_26148725","title":"FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes.","date":"2015","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26148725","citation_count":40,"is_preprint":false},{"pmid":"25944690","id":"PMC_25944690","title":"FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25944690","citation_count":40,"is_preprint":false},{"pmid":"32140858","id":"PMC_32140858","title":"Phosphate-sensing and regulatory mechanism of FGF23 production.","date":"2020","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32140858","citation_count":38,"is_preprint":false},{"pmid":"37053547","id":"PMC_37053547","title":"Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37053547","citation_count":38,"is_preprint":false},{"pmid":"30062428","id":"PMC_30062428","title":"Crosstalk between FGF23- and angiotensin II-mediated Ca2+ signaling in pathological cardiac hypertrophy.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/30062428","citation_count":38,"is_preprint":false},{"pmid":"27704252","id":"PMC_27704252","title":"Extrarenal effects of FGF23.","date":"2016","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/27704252","citation_count":37,"is_preprint":false},{"pmid":"31801907","id":"PMC_31801907","title":"FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31801907","citation_count":37,"is_preprint":false},{"pmid":"33520985","id":"PMC_33520985","title":"Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33520985","citation_count":37,"is_preprint":false},{"pmid":"29843712","id":"PMC_29843712","title":"FGF23C-tail improves diabetic nephropathy by attenuating renal fibrosis and inflammation.","date":"2018","source":"BMC biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29843712","citation_count":37,"is_preprint":false},{"pmid":"22396163","id":"PMC_22396163","title":"FGF23, klotho and vitamin D interactions: What have we learned from in vivo mouse genetics studies?","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22396163","citation_count":36,"is_preprint":false},{"pmid":"38479224","id":"PMC_38479224","title":"ERRγ-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38479224","citation_count":35,"is_preprint":false},{"pmid":"34757587","id":"PMC_34757587","title":"Regulation of FGF23: Beyond Bone.","date":"2021","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/34757587","citation_count":35,"is_preprint":false},{"pmid":"20012997","id":"PMC_20012997","title":"FGF-23 in bone biology.","date":"2009","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20012997","citation_count":35,"is_preprint":false},{"pmid":"23235437","id":"PMC_23235437","title":"Enhanced FGF23 serum concentrations and phosphaturia in gene targeted mice expressing WNK-resistant SPAK.","date":"2012","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/23235437","citation_count":34,"is_preprint":false},{"pmid":"29096595","id":"PMC_29096595","title":"Pleiotropic Actions of FGF23.","date":"2017","source":"Toxicologic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29096595","citation_count":33,"is_preprint":false},{"pmid":"27498418","id":"PMC_27498418","title":"Fgf23 and parathyroid hormone signaling interact in kidney and bone.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27498418","citation_count":33,"is_preprint":false},{"pmid":"30971944","id":"PMC_30971944","title":"The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30971944","citation_count":33,"is_preprint":false},{"pmid":"26943611","id":"PMC_26943611","title":"The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis.","date":"2016","source":"Hormone molecular biology and clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26943611","citation_count":32,"is_preprint":false},{"pmid":"26476373","id":"PMC_26476373","title":"FGF23-regulated production of Fetuin-A (AHSG) in osteocytes.","date":"2015","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/26476373","citation_count":32,"is_preprint":false},{"pmid":"23652554","id":"PMC_23652554","title":"Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.","date":"2013","source":"Contributions to nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/23652554","citation_count":31,"is_preprint":false},{"pmid":"32193252","id":"PMC_32193252","title":"C-FGF23 peptide alleviates hypoferremia during acute inflammation.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32193252","citation_count":30,"is_preprint":false},{"pmid":"30852297","id":"PMC_30852297","title":"Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction.","date":"2019","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30852297","citation_count":29,"is_preprint":false},{"pmid":"33853949","id":"PMC_33853949","title":"Orphan nuclear receptor ERR-γ regulates hepatic FGF23 production in acute kidney injury.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33853949","citation_count":28,"is_preprint":false},{"pmid":"31377240","id":"PMC_31377240","title":"Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone.","date":"2019","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/31377240","citation_count":27,"is_preprint":false},{"pmid":"31968132","id":"PMC_31968132","title":"Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23.","date":"2020","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/31968132","citation_count":26,"is_preprint":false},{"pmid":"22396164","id":"PMC_22396164","title":"FGF23 and the parathyroid.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22396164","citation_count":25,"is_preprint":false},{"pmid":"31350618","id":"PMC_31350618","title":"αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31350618","citation_count":25,"is_preprint":false},{"pmid":"29904273","id":"PMC_29904273","title":"FGF23 and Fetuin-A Interaction in the Liver and in the Circulation.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29904273","citation_count":23,"is_preprint":false},{"pmid":"32729975","id":"PMC_32729975","title":"Influence of FGF23 and Klotho on male reproduction: Systemic vs direct effects.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32729975","citation_count":23,"is_preprint":false},{"pmid":"27125741","id":"PMC_27125741","title":"The FGF23/KLOTHO Regulatory Network and Its Roles in Human Disorders.","date":"2016","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/27125741","citation_count":22,"is_preprint":false},{"pmid":"26125643","id":"PMC_26125643","title":"FGF23 regulation of renal tubular solute transport.","date":"2015","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/26125643","citation_count":22,"is_preprint":false},{"pmid":"29483574","id":"PMC_29483574","title":"Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29483574","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51417,"output_tokens":8011,"usd":0.137208,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17468,"output_tokens":6292,"usd":0.12232,"stage2_stop_reason":"end_turn"},"total_usd":0.259528,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Klotho binds FGF23 and converts FGFR1(IIIc) into a specific high-affinity FGF23 receptor; forced expression of Klotho enabled high-affinity FGF23 binding to cell surfaces and restored FGF23 responsiveness in a renal cell line. Injection of an anti-Klotho monoclonal antibody in wild-type mice induced FGF23 incompetence, establishing Klotho as an obligate co-receptor for endogenous FGF23 function.\",\n      \"method\": \"Renal homogenate binding assay, cell-surface binding with forced Klotho expression, in vivo antibody neutralization, reconstitution of FGFR1(IIIc)/Klotho complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of receptor complex, in vitro binding assays, in vivo antibody neutralization, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"17086194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of a 1:1:1 ternary complex of shed α-klotho ectodomain, FGFR1c ligand-binding domain, and FGF23 shows that α-klotho simultaneously tethers FGFR1c via its D3 domain and FGF23 via its C-terminal tail, conferring complex stability. Dimerization and receptor activation still require heparan sulfate. The α-klotho structure is incompatible with glycosidase activity, establishing it as a non-enzymatic scaffold protein.\",\n      \"method\": \"X-ray crystallography (atomic structure of ternary complex), structural functional validation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic resolution crystal structure with mechanistic interpretation, single rigorous study with direct structural evidence\",\n      \"pmids\": [\"29342138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGF23 causes pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway in a klotho-independent manner. Intramyocardial or intravenous FGF23 injection in wild-type mice produced LVH. Treatment with an FGF-receptor blocker attenuated LVH in a CKD model.\",\n      \"method\": \"Isolated rat cardiomyocyte hypertrophy assay, intramyocardial/intravenous FGF23 injection in mice, FGF-receptor blocker treatment in CKD animal model, klotho-deficient mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro cardiomyocyte assay with pathway identification, multiple in vivo mouse models, pharmacological blockade, replicated across several experimental systems in one study\",\n      \"pmids\": [\"21985788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF23 induces cardiac hypertrophy and LVH specifically via FGFR4 (not other FGFRs); specific pharmacological blockade of FGFR4 attenuated established LVH in the 5/6 nephrectomy CKD rat model and protected aging mice from LVH. FGF23 also increases cardiac contractility via FGFR4.\",\n      \"method\": \"FGFR4-specific pharmacological blockade in CKD rat model (5/6 nephrectomy), FGFR4 knockout aging mice, in vitro cardiomyocyte assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and pharmacological blockade in multiple in vivo models with defined phenotypic readouts\",\n      \"pmids\": [\"28512310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF23 directly regulates membrane abundance of the Na+:Cl- cotransporter NCC in distal renal tubules via a signaling cascade involving the FGF receptor/αKlotho complex → ERK1/2 → SGK1 → WNK4. Gain of FGF23 function increased distal tubular Na+ uptake and NCC membrane expression, causing volume expansion, hypertension, and cardiac hypertrophy in an αKlotho- and dietary Na+-dependent fashion. NCC inhibitor chlorothiazide abrogated these effects.\",\n      \"method\": \"Recombinant FGF23 injection in wild-type mice, Fgf23- and αKlotho-deficient mouse models, Hyp mice, pharmacological NCC inhibition, western blot for NCC membrane expression\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mouse models (loss- and gain-of-function), defined signaling cascade, pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"24797667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF23 inhibits neutrophil (PMN) recruitment by binding FGFR2 on PMNs, activating protein kinase A (PKA), and thereby inhibiting activation of the small GTPase Rap1, which counteracts selectin- and chemokine-triggered β2 integrin activation. FGF23 neutralization in CKD mice restored leukocyte recruitment; FGFR2 knockdown on PMNs rescued host defense.\",\n      \"method\": \"Intravital microscopy, in vitro PMN adhesion/arrest/migration assays, FGF23 neutralization in CKD mouse models, FGFR2 knockdown, PKA knockdown\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vitro and in vivo methods, defined signaling pathway (FGFR2→PKA→Rap1→β2 integrin), genetic knockdown validation\",\n      \"pmids\": [\"26878171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FGF23-induced reductions in renal NaPi2a (sodium-phosphate cotransporter type IIa) expression and 1α-hydroxylase mRNA are independent of the 1,25(OH)2D/VDR signaling system, demonstrated by FGF23 administration to VDR-null mice. FGF23 production is regulated by VDR-independent pathways including calcium, whereas dietary phosphate-stimulated FGF23 production required VDR.\",\n      \"method\": \"Recombinant FGF23 administration to VDR knockout mice, measurement of NaPi2a protein abundance, 1α-hydroxylase and 24-hydroxylase mRNA, dietary manipulation\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout model with recombinant protein administration, multiple molecular endpoints, VDR-independent mechanism clearly established\",\n      \"pmids\": [\"15998839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kidney-derived glycerol-3-phosphate (G-3-P) stimulates bone and bone marrow FGF23 production through local GPAT-mediated lysophosphatidic acid (LPA) synthesis, which acts via LPA receptor 1 (LPAR1). Acute kidney injury rapidly increased circulating G-3-P, and the AKI-induced rise in FGF23 was abrogated by GPAT inhibition or Lpar1 deletion.\",\n      \"method\": \"Aptamer-based proteomics and LC-MS metabolomics of human renal venous plasma, exogenous G-3-P administration in mice, GPAT inhibition, Lpar1 genetic deletion, AKI mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human metabolomics identifying G-3-P, mechanistic validation in mice with genetic deletion and pharmacological inhibition across multiple orthogonal methods\",\n      \"pmids\": [\"32065590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"C-terminal FGF23 (Cter-FGF23) cleaved peptides, derived mainly from osteocytes via furin-dependent cleavage, bind BMP2 and BMP9 and prevent BMP-induced hepcidin production in the liver, thereby increasing iron availability during acute inflammation. Osteocyte-specific Fgf23 deletion and osteocyte-specific Furin deletion both reduced Cter-FGF23 and worsened iron deficiency during inflammation.\",\n      \"method\": \"Osteocyte-specific Fgf23 and Furin knockout mice, co-administration of Cter-FGF23 with BMP2/BMP9, genetic overexpression of Cter-Fgf23, measurement of hepcidin and serum iron\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mouse models (osteocyte-specific KO), BMP binding shown, mechanistic pathway established with multiple orthogonal approaches\",\n      \"pmids\": [\"37053547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF23 undergoes FAM20C-mediated phosphorylation that targets it to proteolysis by the subtilisin-like proprotein convertase FURIN, resulting in secretion of FGF23 fragments. O-glycosylation of FGF23 by GALNT3 prevents this proteolysis, resulting in secretion of biologically active intact FGF23.\",\n      \"method\": \"Review synthesizing genetic/biochemical evidence from prior studies; described as established mechanisms from multiple prior works\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mechanistic details compiled from established literature but this paper is a review; individual supporting experiments are in primary sources not independently assessed here\",\n      \"pmids\": [\"33338030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Pro-inflammatory cytokines TNF, IL-1β, TWEAK, and bacterial LPS up-regulate Fgf23 mRNA in osteocyte-like IDG-SW3 cells and human bone via NF-κB-dependent mechanisms. These stimuli also increased GALNT3 expression (which protects FGF23 from cleavage), and intact FGF23 protein increased in the presence of furin inhibitors, indicating that furin-mediated cleavage critically controls active FGF23 secretion.\",\n      \"method\": \"IDG-SW3 osteocyte cell line stimulation, human bone samples, qRT-PCR, ELISA, NF-κB inhibition, furin inhibition assays\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell culture and human tissue, NF-κB pathway validated pharmacologically, furin cleavage role shown with inhibitor, two orthogonal approaches in single lab\",\n      \"pmids\": [\"25458698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Osteocyte-specific deletion of FGFR1 (Fgfr1Dmp1-cKO) reduced FGF23 expression in bone by 50% and serum FGF23 by 3-fold. FGF23 promoter activity in osteoblasts was stimulated by FGFR1 activation and inhibited by dominant-negative FGFR1(TK-), PLCγ, and MAPK inhibitors. FGF2 stimulated FGF23 translation via a FGFR1- and PI3K/Akt-dependent mechanism, establishing autocrine/paracrine FGFR1 signaling as a regulator of FGF23 production.\",\n      \"method\": \"Osteocyte-specific conditional Fgfr1 knockout (Dmp1-Cre), TOPflash luciferase reporter, FGF23 promoter-luciferase assay, dominant-negative FGFR1 overexpression, pharmacological pathway inhibitors\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockout in vivo combined with in vitro reporter assays and pharmacological pathway dissection, multiple orthogonal approaches\",\n      \"pmids\": [\"25089825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FGF23 activates the Raf/MEK/ERK signaling pathway and induces EGR1 expression via FGFR1 in HEK293 cells, and also phosphorylates FRS2α. Extracellular phosphate activates the same cascade via PiT-1 (type III Na+/Pi cotransporter) converging on FGFR1, with FGFR1 knockdown abolishing Pi-induced ERK1/2 and FRS2α phosphorylation.\",\n      \"method\": \"HEK293 cell transfection with recombinant proteolysis-resistant FGF23[R179Q], ERK1/2 phosphorylation assays, FRS2α phosphorylation, FGFR1 knockdown, FGFR1 overexpression, PiT-1 knockdown, MEK inhibitor\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple knockdown and overexpression experiments in cell culture, defined signaling cascade, single lab\",\n      \"pmids\": [\"20717920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF23 acts on the parathyroid gland via the Klotho-FGFR1c receptor complex to decrease PTH mRNA expression and PTH secretion through activation of the MAPK pathway. In CKD, parathyroid resistance to FGF23 is caused by down-regulation of the Klotho-FGFR1 complex in hyperplastic parathyroid glands.\",\n      \"method\": \"Parathyroid cell experiments, MAPK pathway activation assays, Klotho-FGFR1 expression analysis in CKD parathyroid tissue (human and animal)\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway identified (MAPK) in parathyroid cells, human and animal tissue analysis, but largely a review with primary experimental citations; single lab evidence for resistance mechanism\",\n      \"pmids\": [\"20010546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGF23 acts directly on the parathyroid gland via the Klotho-FGFR1 complex to decrease PTH synthesis and secretion through activation of the MAPK pathway. In advanced experimental uremia, parathyroids do not respond to administered FGF23 by MAPK activation or PTH inhibition, correlating with down-regulation of parathyroid Klotho-FGFR1. PTH directly increases FGF23 expression by osteoblast-like cells, and parathyroidectomy reduces FGF23 in CKD models.\",\n      \"method\": \"FGF23 administration to uremic rats, MAPK pathway activation assays in parathyroid tissue, parathyroidectomy experiments, osteoblast culture with PTH\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro experiments with signaling pathway validation, but review chapter summarizing work from one group\",\n      \"pmids\": [\"22396164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphate directly enhances Fgf23 transcription in UMR-106 osteoblastic cells by stimulating NADPH oxidase-induced reactive oxygen species (ROS) production, which activates the MEK-ERK signaling pathway. Phosphonoformate (sodium-phosphate cotransporter inhibitor), NADPH oxidase inhibitor apocynin, and MEK inhibitor PD98059 all blocked phosphate-induced Fgf23 expression and promoter activity. Phosphate did not affect Fgf23 mRNA stability.\",\n      \"method\": \"UMR-106 cell culture, Fgf23 promoter-luciferase assay, ROS measurement (fluorescence), pharmacological inhibitors (apocynin, PD98059, phosphonoformate), mRNA stability assay\",\n      \"journal\": \"Journal of bone and mineral metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assay plus ROS measurement plus multiple pharmacological inhibitors, single lab, cell culture only\",\n      \"pmids\": [\"25792238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Aldosterone up-regulates Fgf23 transcription and secretion via mineralocorticoid receptor activation, involving SGK1, NF-κB, and store-operated Ca2+ entry (SOCE). In osteoblastic UMR-106 cells, aldosterone enhanced SOCE and Fgf23 mRNA, effects reversed by mineralocorticoid receptor blockers (spironolactone, eplerenone), SGK1 inhibitor, NF-κB inhibitor, and Ca2+ channel blocker. In vivo, DOCA treatment and salt depletion elevated serum FGF23.\",\n      \"method\": \"UMR-106 cell culture, Fura-2 Ca2+ imaging, SOCE measurement, qRT-PCR, DOCA treatment and salt depletion in mice, serum FGF23 ELISA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro pathway dissection with multiple pharmacological inhibitors, in vivo confirmation, single lab\",\n      \"pmids\": [\"26773502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF23 promotes cardiac hypertrophy via FGF receptor 4-dependent activation of phospholipase Cγ/calcineurin/NFAT signaling, independent of klotho. FGF23 expressed in cardiac myocytes also stimulates pro-fibrotic factors in myocytes to induce fibrosis-related pathways in fibroblasts in a paracrine manner.\",\n      \"method\": \"In vitro neonatal rat ventricular myocyte (NRVM) hypertrophy assays, FGFR4 blockade, PLCγ/calcineurin/NFAT pathway analysis, co-culture experiments\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling pathway, in vitro assays, pharmacological blockade, but review paper synthesizing findings; primary experiments from multiple labs\",\n      \"pmids\": [\"29892269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF23-mediated activation of local renin-angiotensin-aldosterone system (RAAS) in the heart promotes cardiac hypertrophy and fibrosis. In neonatal rat ventricular myocytes and fibroblasts, FGF23 stimulated RAAS gene expression; FGF23-mediated hypertrophy and NFAT target gene induction were attenuated by cyclosporine A, losartan, and spironolactone. FGF23 also induced TGF-β and CTGF in cardiac fibroblasts, suppressed by losartan and spironolactone.\",\n      \"method\": \"5/6 nephrectomy rat model, neonatal rat ventricular myocytes and cardiac fibroblasts (NRVM, NRCF), qPCR, western blot, pharmacological inhibition (losartan, spironolactone, cyclosporine A)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo CKD model and in vitro cell assays, pharmacological rescue, single lab\",\n      \"pmids\": [\"31540546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FGF23 activates nuclear Ca2+-regulated CaMKII-HDAC4 pathway and induces IP3-mediated Ca2+ release from nucleoplasmic Ca2+ stores in neonatal rat ventricular myocytes (NRVMs), similar to angiotensin II. FGF23-induced hypertrophy was attenuated by losartan (ATII receptor antagonist), and FGF23 increased intracellular ATII peptide expression and secretion in NRVMs, suggesting FGF23-mediated hypertrophy involves local angiotensin II production.\",\n      \"method\": \"NRVM Ca2+ imaging, cell area measurement, hypertrophic gene expression, losartan treatment, ATII peptide measurement\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined Ca2+ signaling pathway, pharmacological rescue with ATII receptor blocker, single lab, in vitro only\",\n      \"pmids\": [\"30062428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"During acute kidney injury, hepatic FGF23 production is driven by the orphan nuclear receptor ERR-γ, which is induced by circulating IL-6. Ectopic ERR-γ overexpression was sufficient to induce hepatic FGF23. Liver-specific ERRγ knockout or ERRγ inverse agonist treatment decreased hepatic FGF23 mRNA and plasma FGF23 levels in AKI mice.\",\n      \"method\": \"Folic acid-induced AKI mouse model, liver-specific ERRγ knockout, ERRγ overexpression, IL-6 neutralizing antibody and recombinant IL-6 administration, ERRγ inverse agonist\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout, ectopic overexpression, cytokine neutralization, pharmacological inhibition, and human patient correlation, multiple orthogonal methods\",\n      \"pmids\": [\"33853949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatic FGF23 is transcriptionally regulated by ERR-γ in response to alcohol-mediated activation of cannabinoid receptor type 1 (CB1R). FGF23-LKO mice showed decreased hepatic CYP2E1 expression, reduced oxidative stress, and improved alcoholic liver disease, establishing a CB1R-ERRγ-FGF23-CYP2E1 axis in alcoholic liver injury.\",\n      \"method\": \"Hepatocyte-specific knockouts (CB1R-LKO, ERRγ-LKO, FGF23-LKO), chronic alcohol feeding, ERRγ inverse agonist treatment, CYP2E1 expression analysis, liver injury assessment\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple tissue-specific genetic knockouts, pharmacological inhibition, defined CB1R→ERRγ→FGF23→CYP2E1 pathway with mechanistic validation\",\n      \"pmids\": [\"38479224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGF23 signals through a klotho/FGFR complex in multiple myeloma cells (expressing both klotho and FGFR), increasing EGR1 and its target heparanase mRNA. FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23 and suppressed myeloma growth in bone.\",\n      \"method\": \"MM cell line stimulation with FGF23, mRNA expression (EGR1, heparanase), FGFR inhibitor NVP-BGJ398, in vivo bone growth model, klotho/FGFR expression analysis by IHC and western blot\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro signaling assays, pharmacological FGFR blockade in vitro and in vivo, single lab\",\n      \"pmids\": [\"25944690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"High extracellular phosphate directly activates FGFR1 in osteocytes/osteoblasts, and downstream intracellular signaling regulates GALNT3 expression, which in turn controls O-glycosylation and the ratio of intact to cleaved FGF23. FGFR1 thus functions as a phosphate-sensing receptor in the regulation of FGF23 production.\",\n      \"method\": \"Cell culture experiments with phosphate stimulation, FGFR1 activation assays, GALNT3 expression analysis, FGF23 protein cleavage measurements\",\n      \"journal\": \"Journal of endocrinological investigation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — described in a review/perspective with reference to authors' own prior findings; limited methodological detail in this abstract, single lab\",\n      \"pmids\": [\"32140858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF23 deficiency in mice leads to hippocampal-dependent cognitive impairment (dose-dependent, established by behavioral testing) without gross structural or developmental brain defects, without change in hippocampal synaptic plasticity, and with only minor impairment to postnatal hippocampal neurogenesis, indicating a distinct brain phenotype from Klotho-deficient mice.\",\n      \"method\": \"Fgf23-deficient mouse model, hippocampal-dependent behavioral tests (cognitive), hippocampal neurogenesis assay, synaptic plasticity measurements\",\n      \"journal\": \"eNeuro\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cognitive phenotype in genetic knockout with multiple behavioral and cellular readouts, single lab\",\n      \"pmids\": [\"30911673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"C-terminal FGF23 (Cter-FGF23) peptide alleviates LPS-induced acute hypoferremia by reducing hepatic and circulating hepcidin. FGF23 is induced as early as pro-inflammatory cytokines by LPS (TLR4 activation), and inhibition of FGF23 signaling with C-terminal FGF23 tail abrogated iron sequestration in liver and spleen.\",\n      \"method\": \"Wild-type mouse LPS model, C-terminal FGF23 peptide administration, hepcidin mRNA and protein measurement, serum iron and transferrin saturation, tissue iron quantification\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological intervention with FGF23 C-tail, multiple iron metabolism endpoints, single lab\",\n      \"pmids\": [\"32193252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGF23 up-regulates AHSG (Fetuin-A) mRNA and protein production in osteocytes via FGF receptor-dependent mechanisms; FGF23 silencing had the opposite effect. FGF23 and AHSG proteins co-localize in both cytoplasm and nucleus of osteocytes, suggesting possible direct interaction.\",\n      \"method\": \"Osteocyte cell culture, FGF23 addition/overexpression/silencing, qRT-PCR, western blot, FGF23 receptor blockade, co-localization by immunofluorescence\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell culture only, single lab, co-localization without formal co-IP or pulldown for interaction\",\n      \"pmids\": [\"26476373\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF23 is a bone-derived (primarily osteocyte-secreted) endocrine hormone that binds a ternary receptor complex of FGFR1c and the non-enzymatic scaffold co-receptor α-Klotho (structure resolved by X-ray crystallography), activating FRS2/RAS/RAF/MEK/ERK1/2 signaling to suppress renal NaPi-IIa/IIc-mediated phosphate reabsorption, inhibit 1α-hydroxylase (reducing 1,25(OH)2D synthesis), and augment distal tubular NCC/TRPV5 expression via ERK1/2→SGK1→WNK4 signaling; FGF23 also acts on the parathyroid via Klotho-FGFR1c to suppress PTH through MAPK activation, while at high concentrations (as in CKD) it acts on klotho-deficient tissues—most importantly the heart via FGFR4—activating calcineurin/NFAT and PLCγ pathways to cause left ventricular hypertrophy, and on neutrophils via FGFR2/PKA/Rap1 to suppress β2 integrin activation and impair innate immunity; FGF23 undergoes post-translational regulation by GALNT3-mediated O-glycosylation (promoting secretion of intact, active hormone) and FAM20C phosphorylation/furin cleavage (producing inactive C-terminal fragments), with the C-terminal fragments having their own biological activity by binding BMP2/BMP9 to suppress hepcidin and increase iron availability during inflammation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF23 is a bone-derived endocrine hormone that controls systemic phosphate and vitamin D homeostasis and, at pathological concentrations, drives organ injury in chronic kidney disease [#0, #6]. Canonical FGF23 signaling requires the co-receptor \\u03b1-Klotho, which converts FGFR1c into a high-affinity FGF23 receptor; structurally, \\u03b1-Klotho is a non-enzymatic scaffold that simultaneously tethers FGFR1c and the FGF23 C-terminal tail, with heparan sulfate required for receptor dimerization and activation [#0, #1]. Through this Klotho-FGFR1c complex FGF23 activates RAS/RAF/MEK/ERK signaling to suppress renal NaPi-IIa and 1\\u03b1-hydroxylase\\u2014independently of vitamin D/VDR signaling [#6, #12]\\u2014and acts on distal tubule to raise NCC membrane abundance via ERK1/2\\u2192SGK1\\u2192WNK4, causing Na+ retention, hypertension, and cardiac hypertrophy [#4]; it also acts directly on the parathyroid gland via Klotho-FGFR1 to suppress PTH through MAPK activation [#13]. In Klotho-independent settings, high FGF23 drives left ventricular hypertrophy by signaling through cardiac FGFR4 to activate PLC\\u03b3/calcineurin/NFAT, with FGFR4 blockade attenuating established LVH [#2, #3], and suppresses neutrophil recruitment by binding FGFR2 and activating PKA to inhibit Rap1-dependent \\u03b22 integrin activation, impairing innate immunity [#5]. FGF23 production by osteocytes is regulated by autocrine/paracrine FGFR1 signaling and by phosphate, PTH, aldosterone, and pro-inflammatory cytokines acting through NF-\\u03baB, ROS/MEK-ERK, and SGK1 pathways [#11, #15, #16, #10], while post-translational processing\\u2014FAM20C phosphorylation and furin cleavage versus GALNT3 O-glycosylation\\u2014determines the ratio of inactive fragments to secreted intact hormone [#9]. The furin-generated C-terminal fragment is itself bioactive, binding BMP2/BMP9 to block hepcidin induction and preserve iron availability during inflammation [#8, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established why FGF23 is tissue-selective despite ubiquitous FGFRs: \\u03b1-Klotho is an obligate co-receptor that converts FGFR1c into a high-affinity FGF23 receptor.\",\n      \"evidence\": \"Renal binding assays, forced Klotho expression, and in vivo anti-Klotho antibody neutralization in mice\",\n      \"pmids\": [\"17086194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the atomic architecture of the ternary complex\", \"Did not address Klotho-independent FGF23 actions\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the structural basis of receptor assembly, showing \\u03b1-Klotho is a non-enzymatic scaffold tethering both FGFR1c and the FGF23 C-terminal tail.\",\n      \"evidence\": \"X-ray crystallography of the 1:1:1 shed \\u03b1-Klotho/FGFR1c/FGF23 ternary complex with functional validation\",\n      \"pmids\": [\"29342138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heparan sulfate-bound dimeric activated state not crystallized\", \"Structures of FGFR4 and FGFR2 complexes not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed FGF23 suppresses renal phosphate transport and 1\\u03b1-hydroxylase through a VDR-independent mechanism, separating its effector actions from vitamin D signaling.\",\n      \"evidence\": \"Recombinant FGF23 administration to VDR-null mice with measurement of NaPi2a, 1\\u03b1- and 24-hydroxylase mRNA\",\n      \"pmids\": [\"15998839\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the renal intracellular signaling cascade\", \"Dietary phosphate-stimulated FGF23 production was VDR-dependent, mechanism unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the canonical FGF23 intracellular cascade and linked it to phosphate sensing through a converging FGFR1 node.\",\n      \"evidence\": \"HEK293 transfection with proteolysis-resistant FGF23[R179Q], ERK1/2 and FRS2\\u03b1 phosphorylation, FGFR1 and PiT-1 knockdown\",\n      \"pmids\": [\"20717920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell line overexpression, not physiological target tissue\", \"Did not require Klotho in this system\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified a Klotho-independent pathological action of FGF23, demonstrating it directly causes cardiomyocyte hypertrophy via FGFR-dependent calcineurin-NFAT signaling.\",\n      \"evidence\": \"Isolated rat cardiomyocyte assays, intramyocardial/IV FGF23 injection, FGF-receptor blockade in a CKD model\",\n      \"pmids\": [\"21985788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not pinpoint which FGFR mediates the cardiac effect\", \"Did not establish PLC\\u03b3 upstream of calcineurin\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the receptor and signaling specificity of FGF23-induced renal Na+ handling, connecting FGF23 to hypertension and volume expansion.\",\n      \"evidence\": \"Gain- and loss-of-function mouse models, NCC membrane western blots, chlorothiazide rescue\",\n      \"pmids\": [\"24797667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reconcile the \\u03b1Klotho-dependent renal effect with Klotho-independent cardiac effects\", \"Long-term cardiovascular consequences not fully traced\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established autocrine/paracrine FGFR1 signaling within bone as a positive regulator of FGF23 production, identifying a feed-forward loop.\",\n      \"evidence\": \"Osteocyte-specific Fgfr1 conditional knockout, FGF23 promoter-luciferase assays, dominant-negative FGFR1 and pathway inhibitors\",\n      \"pmids\": [\"25089825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream physiological ligand activating osteocyte FGFR1 not defined\", \"Quantitative contribution relative to systemic regulators unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked inflammation to FGF23 production, showing cytokines and LPS induce Fgf23 via NF-\\u03baB while furin cleavage gates active hormone output.\",\n      \"evidence\": \"IDG-SW3 osteocyte stimulation and human bone, qRT-PCR/ELISA, NF-\\u03baB and furin inhibitors\",\n      \"pmids\": [\"25458698\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell and tissue model\", \"In vivo causal contribution of NF-\\u03baB not tested by genetic deletion\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Refined how phosphate transcriptionally induces FGF23, implicating NADPH oxidase-derived ROS upstream of MEK-ERK.\",\n      \"evidence\": \"UMR-106 promoter-luciferase, ROS imaging, apocynin/PD98059/phosphonoformate inhibitors, mRNA stability assay\",\n      \"pmids\": [\"25792238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell culture only\", \"Did not connect ROS pathway to FGFR1-mediated phosphate sensing\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified aldosterone/mineralocorticoid receptor as a hormonal driver of FGF23, involving SGK1, NF-\\u03baB, and store-operated Ca2+ entry.\",\n      \"evidence\": \"UMR-106 culture, Fura-2 Ca2+ imaging, MR/SGK1/NF-\\u03baB/Ca2+-channel inhibitors, DOCA and salt depletion in mice\",\n      \"pmids\": [\"26773502\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanism\", \"Tissue-specific genetic confirmation of MR-FGF23 axis lacking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a Klotho-independent immunosuppressive action of FGF23, showing it impairs neutrophil recruitment through FGFR2/PKA/Rap1.\",\n      \"evidence\": \"Intravital microscopy, PMN adhesion assays, FGF23 neutralization in CKD mice, FGFR2 and PKA knockdown\",\n      \"pmids\": [\"26878171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FGF23-FGFR2 engagement not resolved\", \"Relative clinical contribution to CKD infection risk not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified FGFR4 as the specific cardiac receptor for FGF23-induced hypertrophy, providing a therapeutic target.\",\n      \"evidence\": \"FGFR4-specific blockade in 5/6 nephrectomy rats, FGFR4 knockout aging mice, in vitro cardiomyocyte assays\",\n      \"pmids\": [\"28512310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not fully delineate downstream effectors in this study\", \"Whether contractility and hypertrophy share one pathway unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected FGF23 cardiac signaling to nuclear Ca2+/CaMKII-HDAC4 and local angiotensin II, linking it to a hypertrophic gene program.\",\n      \"evidence\": \"NRVM Ca2+ imaging, cell area and hypertrophic gene readouts, losartan treatment, ATII peptide measurement\",\n      \"pmids\": [\"30062428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only\", \"Causal role of local ATII in vivo not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the cardiac mechanism, implicating FGFR4-PLC\\u03b3/calcineurin/NFAT and local RAAS activation in hypertrophy and fibrosis.\",\n      \"evidence\": \"5/6 nephrectomy rats and NRVM/NRCF cultures, losartan/spironolactone/cyclosporine A inhibition (and review synthesis)\",\n      \"pmids\": [\"29892269\", \"31540546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab in vitro emphasis\", \"Integration of RAAS, Ca2+, and NFAT into one circuit not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a non-mineral CNS phenotype, showing FGF23 deficiency causes hippocampal-dependent cognitive impairment distinct from Klotho loss.\",\n      \"evidence\": \"Fgf23-deficient mice, hippocampal behavioral testing, neurogenesis and synaptic plasticity assays\",\n      \"pmids\": [\"30911673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor and signaling pathway in brain unidentified\", \"Cell-autonomous vs systemic mechanism unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a kidney-to-bone metabolite signal, glycerol-3-phosphate acting via LPA/LPAR1, that drives FGF23 production, especially in acute kidney injury.\",\n      \"evidence\": \"Human renal venous metabolomics, exogenous G-3-P in mice, GPAT inhibition, Lpar1 deletion, AKI models\",\n      \"pmids\": [\"32065590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular LPAR1-to-FGF23 transcription link not detailed\", \"Relative importance versus phosphate/PTH regulation unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a hepatic source of FGF23 in injury, showing IL-6-induced ERR-\\u03b3 transcriptionally drives liver FGF23 during AKI.\",\n      \"evidence\": \"Folic acid AKI model, liver-specific ERR\\u03b3 knockout, ERR\\u03b3 overexpression, IL-6 neutralization, ERR\\u03b3 inverse agonist\",\n      \"pmids\": [\"33853949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of hepatic vs bone FGF23 not separated\", \"Whether hepatic FGF23 is intact or cleaved not defined here\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a distinct bioactivity for the C-terminal FGF23 fragment in iron metabolism, alleviating inflammatory hypoferremia by lowering hepcidin.\",\n      \"evidence\": \"WT mouse LPS model, C-terminal FGF23 peptide administration, hepcidin and tissue/serum iron measurements\",\n      \"pmids\": [\"32193252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular receptor/binding partner of the fragment not identified in this study\", \"Single-lab pharmacological intervention\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Consolidated the post-translational control of FGF23 output via FAM20C phosphorylation/furin cleavage versus GALNT3 O-glycosylation.\",\n      \"evidence\": \"Review synthesizing prior genetic and biochemical evidence\",\n      \"pmids\": [\"33338030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review, not primary data\", \"Relative in vivo flux through each branch not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided direct molecular mechanism for C-terminal FGF23 bioactivity, showing it binds BMP2/BMP9 to block BMP-induced hepcidin and preserve iron during inflammation.\",\n      \"evidence\": \"Osteocyte-specific Fgf23 and Furin knockouts, Cter-FGF23 plus BMP2/BMP9 co-administration, Cter-Fgf23 overexpression, hepcidin/iron measurement\",\n      \"pmids\": [\"37053547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Cter-FGF23/BMP binding not resolved\", \"Contribution in chronic vs acute inflammation not delineated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended hepatic FGF23 regulation to alcoholic liver disease through a CB1R-ERR\\u03b3-FGF23-CYP2E1 oxidative-stress axis.\",\n      \"evidence\": \"Hepatocyte-specific CB1R/ERR\\u03b3/FGF23 knockouts, chronic alcohol feeding, ERR\\u03b3 inverse agonist, CYP2E1 and injury readouts\",\n      \"pmids\": [\"38479224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating FGF23-to-CYP2E1 effect not defined\", \"Whether circulating vs autocrine hepatic FGF23 is responsible unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct receptor usage (FGFR1c/Klotho, FGFR4, FGFR2) and the intact-versus-C-terminal forms are integrated to produce tissue-specific physiological versus pathological outcomes remains unresolved.\",\n      \"evidence\": \"No single study reconciles receptor selectivity, fragment bioactivity, and tissue context\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model of receptor/cofactor selection across tissues\", \"Endogenous receptor for the C-terminal fragment's hepcidin effect not molecularly defined\", \"Brain FGF23 signaling pathway unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 4, 5, 12]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 8, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 20, 21]}\n    ],\n    \"complexes\": [\"FGF23\\u2013FGFR1c\\u2013\\u03b1-Klotho ternary receptor complex\"],\n    \"partners\": [\"KL\", \"FGFR1\", \"FGFR4\", \"FGFR2\", \"BMP2\", \"BMP9\", \"GALNT3\", \"FURIN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}